Lutz RJ[au] - Search Results

Year	Number of Results
1951	2
1954	2
1955	1
1973	1
1974	2
1975	2
1977	4
1979	3
1980	1
1983	1
1984	1
1986	4
1987	1
1988	3
1989	2
1990	1
1991	2
1992	6
1994	1
1995	5
1996	1
1998	1
1999	2
2000	4
2001	1
2002	3
2004	2
2005	5
2006	5
2007	4
2008	2
2009	2
2010	2
2011	2
2013	1
2014	1
2015	2
2016	1
2024	0

1

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM. Ab O, et al. Among authors: lutz rj. Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22. Mol Cancer Ther. 2015. PMID: 25904506

2

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. Lewis Phillips GD, et al. Among authors: lutz rj. Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776. Cancer Res. 2008. PMID: 19010901

3

The prenylation of proteins.

Sinensky M, Lutz RJ. Sinensky M, et al. Among authors: lutz rj. Bioessays. 1992 Jan;14(1):25-31. doi: 10.1002/bies.950140106. Bioessays. 1992. PMID: 1546978 Review.

4

Antibody-maytansinoid conjugates for the treatment of myeloma.

Lutz RJ, Whiteman KR. Lutz RJ, et al. MAbs. 2009 Nov-Dec;1(6):548-51. doi: 10.4161/mabs.1.6.10029. Epub 2009 Nov 9. MAbs. 2009. PMID: 20068397 Free PMC article. Review.

5

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.

Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. Blanc V, et al. Among authors: lutz rj. Clin Cancer Res. 2011 Oct 15;17(20):6448-58. doi: 10.1158/1078-0432.CCR-11-0485. Clin Cancer Res. 2011. PMID: 22003072 Review.

6

A review of the applications of physiologically based pharmacokinetic modeling.

Himmelstein KJ, Lutz RJ. Himmelstein KJ, et al. Among authors: lutz rj. J Pharmacokinet Biopharm. 1979 Apr;7(2):127-45. doi: 10.1007/BF01059734. J Pharmacokinet Biopharm. 1979. PMID: 20218010 Review.

7

Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins.

Lutz RJ. Lutz RJ. Biochem Soc Trans. 2000 Feb;28(2):51-6. doi: 10.1042/bst0280051. Biochem Soc Trans. 2000. PMID: 10816098 Review.

8

The construction of a pharmacokinetic model for the disposition of polychlorinated biphenyls in the rat.

Anderson MW, Eling TE, Lutz RJ, Dedrick RL, Matthews HB. Anderson MW, et al. Among authors: lutz rj. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):765-73. doi: 10.1002/cpt1977225part2765. Clin Pharmacol Ther. 1977. PMID: 410580 Review.

9

Physiological pharmacokinetics: an in vivo approach to membrane transport.

Lutz RJ, Dedrick RL, Zaharko DS. Lutz RJ, et al. Pharmacol Ther. 1980;11(3):559-92. doi: 10.1016/0163-7258(80)90042-x. Pharmacol Ther. 1980. PMID: 7003607 Review. No abstract available.

10

Transport barriers in transscleral drug delivery for retinal diseases.

Kim SH, Lutz RJ, Wang NS, Robinson MR. Kim SH, et al. Among authors: lutz rj. Ophthalmic Res. 2007;39(5):244-54. doi: 10.1159/000108117. Epub 2007 Sep 12. Ophthalmic Res. 2007. PMID: 17851264 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

83 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year